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Abstract
Purpose—Adipocytes represent one of the most abundant constituents of the mammary gland.
They are essential for mammary tumor growth and survival. Metabolically, one of the more
important fat-derived factors (“adipokines”) is adiponectin (APN). Serum concentrations of APN
negatively correlate with body mass index and insulin resistance. To explore the association of
APN with breast cancer and tumor angiogenesis, we took an in vivo approach aiming to study its
role in the mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT) mammary
tumor model.
Experimental Design—We compared the rates of tumor growth in MMTV-PyMT mice in
wild-type and APN-null backgrounds.
Results—Histology and micro-positron emission tomography imaging show that the rate of
tumor growth is significantly reduced in the absence of APN at early stages. PyMT/APN knockout
mice exhibit a reduction in their angiogenic profile resulting in nutrient deprivation of the tumors
and tumor-associated cell death. Surprisingly, in more advanced malignant stages of the disease,
tumor growth develops more aggressively in mice lacking APN, giving rise to a larger tumor
burden, an increase in the mobilization of circulating endothelial progenitor cells, and a gene
expression fingerprint indicative of more aggressive tumor cells.
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Conclusions—These observations highlight a novel important contribution of APN in
mammary tumor development and angiogenesis, indicating that APN has potent angio-mimetic
properties in tumor vascularization. However, in tumors deprived of APN, this antiangiogenic
stress results in an adaptive response that fuels tumor growth through mobilization of circulating
endothelial progenitor cells and the development of mechanisms enabling massive cell
proliferation despite a chronically hypoxic micro-environment.
The physiologic role of adipose tissue as a dynamic organ has shown its crucial role in
maintaining normal systemic energy balance, glucose homeostasis, and the immune
response (1, 2). In the context of the mammary gland, the adipocytes are an abundant cell
type in the stroma and are vital for ductal development and survival. This is due largely to
their secretory profile of adipokines such as leptin, adiponectin, hepatocyte growth factor,
collagen VI, interleukin 6, and tumor necrosis factor α (3). Mammary tumor growth is
determined by cell-autonomous effects of epithelial cancer cells as well as by contributions
of the stromal compartment (4–6). Here, we focus on the adipocyte microenvironment of the
mammary gland. Our previous work characterized a broad spectrum of effects mediated by
soluble adipokines on the proliferative, invasive, and angiogenic capacity of ductal epithelial
cells (5, 7), suggestive of major contributions of adipokines to the malignant progression of
breast cancer.
A widely studied adipokine in the area of metabolism is adiponectin (APN; ref. 8). APN is
an adipocyte-specific secretory protein that enhances hepatic insulin sensitivity by
suppressing hepatic glucose output from gluconeogenesis (9, 10) and also affects glucose
uptake in the muscle (11). In addition, it has potent protective effects against inflammation,
adverse lipid profiles, and atherosclerosis. As a result, it is thought to be potently
cardioprotective (11, 12).
Recently, a great deal of attention has been given to the study of the epidemiologic
association between APN levels in circulation and breast cancer incidence. It is generally
accepted that obesity is a risk factor for breast cancer in postmenopausal but not
premenopausal women (13). Because APN levels are inversely correlated with obesity (11),
it has been suggested that the decreased levels of APN may explain the increased risk of
breast cancer in obesity (13, 14). The epidemiologic association between APN levels and
breast cancer incidence suggested an inverse correlation between APN and breast cancer
risk, an association that seems to be stronger for postmenopausal women (14, 15). In vitro
assays have studied the APN-mammary cancer axis, suggesting an inhibitory role for APN
in mammary tumor growth (16, 17). Similar results were obtained after intratumoral
injection of APN into fibrosarcoma tumors (18). In the majority of these cases, bacterially
produced forms of APN were used either in vitro or in the xenograft models, conditions with
limited relevance for the physiologic action of endogenous, full-length APN, and
autochthonous tumors. Due to its highly complex tertiary and quaternary structure, APN has
to be synthesized in a mammalian production system to recapitulate the complex nature of
its endogenous counterpart (9). In addition, xenograft models may not accurately predict the
antiangiogenic and antitumor responses in human tumors (19, 20).
Thus, we took a direct in vivo approach, using our previously generated APN knockout
(KO) mice (21), to decipher the role of APN and its effect on mammary tumor growth with
the widely used mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT)
model, a spontaneous mammary tumor model (22). This tumor model has been shown to
recapitulate many processes found in human breast cancer progression both morphologically
and in the pattern of expression of biomarkers associated with poor prognosis (23). The
APN KO mice develop diet- and obesity-induced insulin resistance (21, 24) and an impaired
angiogenic response to ischemia (25), but have, in an unchallenged state, minimal
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phenotypic manifestations. We observed that in early stages of tumor progression, lack of
APN delays tumor growth by inhibiting angiogenesis in a paracrine and/or endocrine
fashion.
Despite the defects in angiogenesis in early stages of tumorigenesis in APN KO mice, tumor
growth persisted, leading to rapid tumor growth at later stages of carcinoma. This involved
increased levels of vascular endothelial growth factor (VEGF)-A in the tumor, the
mobilization of circulating endothelial progenitor cells (CEP), and the emergence of a
vasculature with normal appearance as opposed to the dilated and distorted shape
characteristic of tumor vessels. We hypothesized that in mice lacking APN, the
antiangiogenic stress at early stages leads to an adaptation mechanism during which CEPs
are mobilized to contribute to tumor growth, similar to other tumor models undergoing
antiangiogenic stress (26–28).
Combined, our observations indicate that APN has potent angio-mimetic properties in the
early steps of tumor vascularization where mice lacking APN have a lagging angiogenic
response. However, this antiangiogenic stress triggers an adaptive reaction that fuels tumor
growth at later stages. The present data suggest a possible mechanism for the increased risk
and poorer prognosis seen in breast cancer patients with low serum APN levels (such as
obese women) due to acquired adaptation of tumors to antiangiogenic stress.
Materials and Methods
Animals
All animal experimental protocols were approved by the Institute for Animal Studies of the
Albert Einstein College of Medicine and by the Institutional Animal Care and Use
Committee of University of Texas Southwestern Medical Center at Dallas. Mice were
maintained as described previously (29). Experiments presented were done on a mixed C57/
Bl6 and FVB background or a pure FVB background (an excess of nine backcrosses; Figs.
1D, 2, 3, 5, and 6; Supplementary Figs. S1C–D and S2). The majority of experiments were
done on both genetic backgrounds with similar results. Double heterozygous PyMT/ APN
males were crossed with APN heterozygous females to obtain littermates that are deficient
for APN or wild type (WT). Further experimental cohorts were generated by crossing the
heterozygous PyMT/APN KO males to APN KO females, and male heterozygous PyMT to
WT females (21). Intermittently, animals were bred as male PyMT/APN heterozygous at
both loci crossed to APN heterozygous females. Mammary tumor development was
compared between age-matched females of PyMT and PyMT/APN null mice. For detection
of mammary tumor volume, mice were monitored biweekly. Tumor diameter was measured
with a caliper, and tumor volume calculated as (H × W2)/2. APN-over-expressing mice were
previously obtained and characterized (29).
Whole-mount staining and histology of mammary gland
For histology, inguinal mammary glands were fixed for 24 h in 10% normal buffered
formalin (Fisher) and embedded in paraffin. Five-micrometer sections were stained with
H&E; two to three sections per mouse were examined for tumor staging in a blind fashion
and staged as described previously (23). Whole-mount staining was done as described,7
imaged on a Stemi SV11 stereo dissection microscope, and analyzed for lesion area using
Image J software.
7http://mammary.nih.gov/
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Morphologic analysis of mammary gland development
To determine ductal lengths, mammary gland whole-mount preparations were analyzed by
measuring the distance of the three longest ducts from the edge of the 4th mammary gland at
the interface with the 5th mammary gland to the leading edge of the mammary gland.
Terminal end buds were counted in the whole mammary gland.
Peroxisome proliferator–activated receptor-γ agonist regimen
The peroxisome proliferator–activated receptor-γ (PPARγ) agonist 2-(2-(4-phenoxy-2-
propylphenoxy)ethyl)indole-5-acetic acid (COOH) was a kind gift from Merck Research
Laboratories. The drug was mixed with a standard chow diet powder at 10 mg/kg body
weight/d and mice were treated from 4 until 9 wk of age. The mice were subjected to tail
bleeding before and during the course of the treatment.
Immunohistochemistry analysis—CD31 and terminal deoxyribonucleotidyl transferase–
mediated dUTP nick end labeling
Inguinal mammary glands were evaluated for the presence of microvessels on sections fixed
24 h in Zinc Fixative (BD Pharmingen) and stained with antimouse platelet endothelial cell
adhesion molecule/CD31 antibody (BD Pharmingen) overnight at 4°C (1:30). Biotinylated
secondary antibodies were detected with a DAB Substrate Chromagen System
(DakoCytomation). The CD31-positive blood vessels in PyMT and PyMT/APN KO derived
specimens were counted in four fields having the maximal number of CD31-positive
staining per unit area of a section [modification of Weidner et al. (30)]. These were averaged
to calculate the micro-vessel density. Vessel imaging on frozen sections was carried out with
a 1:50 dilution of antimouse platelet endothelial cell adhesion molecule/CD31 antibody (BD
Pharmingen) and a secondary antibody labeled with Alexa Fluor 488 at 1:200 (Molecular
Probes). Nuclei were detected with 4′,6-diamidino-2-phenylindole. Terminal
deoxyribonucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining was
done according to the manufacturer’s protocol (Chemicon), and 10 random fields from areas
of lesions were imaged per mouse for further analysis. Sections were imaged using the Zeiss
Axioskop Plus with the AxioCam MRc camera or Olympus IX81 microscope.
In vivo vessel labeling
Texas red–conjugated dextran (MW 70,000; Molecular Probes) was prepared at 6.2 mg/mL
in PBS. One hundred microliters were injected i.v., and 5 min after the injection, mice were
sacrificed and inguinal mammary glands were fixed in 10% buffered formalin to be
processed by standard procedures (6). For analysis, samples were further stained with 4′,6-
diamidino-2-phenylindole and imaged using the Olympus IX81 microscope. Every second
field of tissue section was imaged, of which 10 random images per mouse were further
quantified using Image J software.
APN, leptin, insulin, and glucose measurements
APN was measured from tail blood with a mouse adiponectin RIA kit (LINCO Research) or
by Western blot analysis with rabbit polyclonal anti-mouse APN antibody. The bands were
detected by the Odyssey Infrared Imaging System (LI-COR) and band intensity was
quantified with Odyssey v1.2 software (LI-COR Biotechnology). Leptin levels were
measured using the mouse leptin Elisa kit (LINCO Research). Insulin, glucose, and oral
glucose tolerance tests were done as described (29).
APN neutralization and APN injections
For APN neutralization experiments, 5-wk-old PyMT females were injected i.p. for a 2-wk
period with either antimouse APN monoclonal antibodies (clones 14 and 45) or purified
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mouse IgGs (Sigma) at 50 μg per mouse every 3rd day (31). APN protein levels were
monitored from tail blood by Western blot analysis.
For APN injections, APN KO and WT male littermates were injected with a preparation of
APN enriched in high molecular weight form (~70% of high molecular weight). Mice were
anesthetized briefly with isoflurane, and APN was delivered through retro-orbital injections
at a concentration of 1 μg/g body weight. Injections were done at 10 a.m. and 6 p.m. on day
1 and at 10 a.m. on day 2. After the last injection, food was removed and animals were
fasted for 4 h before isolation of tissues. Epididymal fat was collected and flash-frozen in
liquid nitrogen.
In vivo Matrigel plug assays
Female mice (10–12 wk of age) were briefly anesthetized and injected s.c. at the abdominal
upper midline with 0.5 mL of Matrigel (BD Biosciences) either supplemented with 100 ng/
mL of basic fibroblast growth factor (FGF; PeproTech, Inc.) or without basic FGF as a
negative control. Mice were sacrificed 10 d after injection and Matrigel plugs were excised
and fixed in Zinc Fixative for 24 h at room temperature. For histologic analysis, paraffin-
embedded sections were stained for H&E. A total of nine sections per Matrigel were imaged
in regions of highest population. Cell density per Matrigel area was quantified using Image J
software.
[18F]Fluorodeoxyglucose positron emission tomography imaging
PyMT and PyMT/APN KO mice were fasted 2 to 3 h before a tail vein injection of
[18F]fluorodeoxyglucose ([18F]FDG; 300 μCi). One hour after injection, mice were
subjected to positron emission tomography (PET) scanning with the Concorde
Microsystems R4 microPET Scanner. Animals were imaged while anesthetized through
inhalation with isoflurane. Image acquisition was done using the MicroPET Manager with
the ASPIRO dedicated software. For analysis, manual regions of interest were defined
around areas of visually identified mammary gland activity. Successive two-dimensional
slices (each 1.2 mm thick in the axial images), after stacking, derived a volume fitted to each
mammary gland. The counts per cubic centimeter within this volume multiplied by the fitted
volume provided total percent of injected dose against the calibrated injection activity. The
glucose uptake was measured for all 10 mammary glands by calculating the percentage of
uptake in the mammary gland relative to the injected dose of the [18F]FDG normalized to
body weight.
RNA isolation and analysis
Mice were sacrificed, and tissue was immediately harvested and frozen in liquid nitrogen.
RNA was isolated from frozen mammary gland tissue by using the Qiagen RNeasy Lipid
tissue kit following the manufacturer’s protocol. cDNA was synthesized from 5 μg RNA
using Superscript III and oligo dT (Invitrogen). All PCR reactions were normalized to actin
mRNA. Quantitative PCR, using SYBR Green I master mix, was done in the Roche
Lightcycler 480. Primer sequences are listed in Supplementary Fig. S4.
Flow cytometry
Blood was obtained from anesthetized mice through cardiac puncture and was followed by
red blood lysis. Cells were stained with FITC-, allophycocyanin-, phycoerythrin-, or biotin-
conjugated antibodies against murine CD45 (e-Biosciences), CD31 (BioLegend), VEGF
receptor (VEGFR)-1 (R&D), and VEGFR-2 (R&D). CEPs were identified by double
positivity for VEGFR-2 and CD31 and double negativity for VEGFR-1 and CD45. Viable
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cells were distinguished from dead cells by using 4′,6-diamidino-2-phenylindole staining.
Cells were measured by LSR II flow cytometer and analyzed using FlowJo software.
Body composition analysis
Body composition was measured using an Echo magnetic resonance imaging system (Echo
Medical Systems).
Gene expression profiling for animals injected with APN
Male animals were euthanized by CO2 asphyxiation 4 h after the final treatment dose, and
epididymal white adipose tissue was harvested and flash-frozen in liquid nitrogen. Total
RNA was isolated after homogenizing the frozen tissues in Trizol reagent (Invitrogen) and
processed using RNeasy kits (Qiagen) according to the manufacturers’ instructions.
Microarray processing was done as previously described (32). Briefly, labeled cRNA was
hybridized for 48 h onto Agilent 60-mer two-color spotted micro-arrays. Individual strain or
compound treatment samples (including individual control or vehicle treatment samples)
were hybridized against a control or vehicle treatment pool. Fold change and P values were
generated by averaging replicates (two to three replicates per strain or treatment) and using
the Rosetta Resolver v6.0 software (Rosetta Inpharmatics LLC, a wholly owned subsidiary
of Merck & Co., Inc.). Fold change values represent the difference in regulation of the
treatment samples versus the control samples, with a positive value signifying up-regulation
following treatment and vice versa.
Gene expression profiling for late-stage tumors
cDNA synthesis was done on pooled RNA from two to three animals per group. Three
independent groups per genotype were hybridized to an Illumina mouse whole-genome
expression beadchip MouseWG-6. Microarray data were analyzed using Partek Genomic
Suite Software and Ingenuity Pathways Analysis. For the Ingenuity Pathways Analysis,
genes were filtered using the criteria P < 0.03.
Statistical analysis
Results are shown as mean ± SE of all experiments combined. Experiments were done thrice
independently (except the Matrigel in vivo assays and PET imaging, which were repeated
twice independently). Statistical analysis was done by Student’s t test or two-way ANOVA
analysis and subsequent Tukey test using Prism 4.0 or SigmaStat version 2.03. Significance
was accepted at P ≤ 0.05.
Results
Mammary tumorigenesis in PyMT/APN KO mice is delayed
We sought to test whether MMTV-PyMT–driven mammary tumor growth is affected by the
absence of APN. Having shown that lack of APN is dispensable for mammary development
(Supplementary Fig. S1A and B), in contrast to the altered ductal architecture in mice
overexpressing APN (Supplementary Fig. S1C and D), we decided to focus on the
phenotypic analysis of the loss of function of APN rather than the gain-of-function model.
Whole-mount preparations were analyzed for mammary tumor growth at 5 and 7 weeks of
age. Lesion areas in PyMT and PyMT/APN KO mice were comparable at 5 weeks of age,
yet mice lacking APN showed a 50% reduction in lesion area compared with PyMT by 7
weeks of age (14.1 ± 2.3 versus 7 ± 0.7 mm2; Fig. 1A, top and bottom). Similarly, a
histologic analysis of mammary glands examined at 7 weeks of age revealed that 38% of the
PyMT have transitioned into the malignant stage (i.e., early carcinoma or late carcinoma
stage), in contrast to only 15% of the PyMT/APN KO mice (Fig. 1B). In addition, PyMT/
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APN KO had a delayed onset of palpable tumors compared with PyMT mice (data not
shown). This time course analysis of the inguinal glands suggests that mammary
tumorigenesis may critically depend on APN during the early stages of tumor progression.
APN neutralization mimics PyMT/APN KO phenotype
Whereas the genetic model with a disruption of the APN gene has great advantages, we
cannot formally rule out the possibility that the absence of APN during development causes
secondary effects that escaped our analysis. To address this issue in a more acute setting, we
took advantage of two monoclonal antibodies that we have generated against mammalian-
produced recombinant mouse APN (31). This injection protocol effectively triggers the
clearance of circulating APN, thereby lowering its concentrations in serum sharply by 75%
to 80%. As a control, mice were injected with nonimmune mouse IgGs, a process that did
not alter APN levels in circulation (Fig. 1C, top). Because the APN-null model suggested a
critical involvement of APN around 7 weeks of age in PyMT mice, we started the antibody
treatment at week 5 and maintained the systemic lowering of APN for 2 weeks with repeated
injections of antibodies every 3 days. Consistent with the chronic depletion of APN,
lowering of APN levels with an antibody-mediated approach showed similar trends with a 2-
fold reduction in lesion area, suggesting that APN plays an important role in maintaining
mammary tumor progression at this stage (Fig. 1C, bottom).
PPARγ agonists accelerate tumorigenesis—a gain-of-function analysis
PPARγ, a member of the nuclear hormone receptor superfamily, is an integral regulator of
energy homeostasis and has a central role in the differentiation of adipocytes (33). It has also
been shown to regulate cell growth and differentiation of a variety of cancer cells, yet its
involvement in the different cancer models is controversial (34). Clinically, APN circulating
levels are highly up-regulated in response to treatment with PPARγ agonists, such as the
thiazolindinediones (35). This up-regulation of APN is an integral component of the
antidiabetic activity of these compounds. In light of the pluripotent effects of PPARγ
agonists that include up-regulation of APN, this is an effective tool to test for the effects of
elevated systemic APN levels on mammary gland tumor development. Starting at 4 weeks
of age, PyMT mice were fed a standard chow diet or a standard chow diet supplemented
with the PPARγ agonist COOH for a duration of 5 weeks. Measurements of circulating APN
showed a 3-fold increase in APN serum levels by day 6 of treatment (data not shown). An
integrated assessment of whole-mount analysis shows a 35% increase in lesion area in
PyMT mice treated with the PPARγ agonist COOH compared with control PyMT. This is in
contrast to a more modest increase of 21% in lesion area in PyMT/APN KO mice treated
with PPARγ agonist compared with control PyMT/APN KO (Fig. 1D). These observations
are consistent with the notion that PPARγ activators may promote mammary tumor growth
at early stages partially through induction of APN. This may be generally relevant for all
tumor types invading stromal compartments enriched in adipocytes.
Loss of APN predisposes to reduced tumor glucose uptake and increased tumor-
associated death
PET imaging is a valuable method that is widely used clinically and in animal models of
cancers, allowing to monitor the presence and progression of tumors using a positron
emitting tracer. To further monitor the mammary tumor progression, PET imaging was
applied using [18F]FDG as a measurement of tumor glucose uptake (36). At 9 weeks of age,
in accordance with the dramatic increase of metabolism that occurs during tumor
development (36), [18F]FDG uptake was elevated in the mammary glands of PyMT mice. In
contrast, only modest levels of [18F]FDG were accumulated in the mammary glands of age-
matched PyMT/ APN KO animals. The glucose uptake was measured for all 10 mammary
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glands, showing an 11-fold increase in the [18F]FDG uptake in PyMT mammary glands
compared with age-matched PyMT/APN KO mammary glands (Fig. 2A).
A histologic examination at this age group revealed necrotic regions in 20% of PyMT/APN
KO mice. In contrast, none of the age-matched PyMT presented such characteristics (Fig.
2B). TUNEL staining revealed a 43% increase in TUNEL-positive cells in mammary lesions
of PyMT/APN KO compared with PyMT mice (Fig. 2C). This suggests that lack of APN at
this time frame of tumor progression limits the availability of glucose and other nutrients for
the tumor environment, leading to a nutrient-deprived cell mass susceptible to cell death and
limiting tumor progression.
APN as a positive regulator of angiogenesis
Previous work has proposed a role for APN in vessel remodeling and promotion of
angiogenesis in an in vivo hind limb model of ischemia (25, 37). To obtain a comprehensive
overview of the angiogenic potential of APN, independent of tumor cells, WT mice were
exposed to a series of APN injections for 2 days, followed by microarray gene expression
profiling of white adipose tissue. The mRNA expression profile points to an induction of
key proangiogenic markers, the most robust effect being on VEGF-A (1.6-fold), VEGF-B
(1.5-fold), VEGFR2 (1.65-fold), and VEGFR1 (1.4-fold; Fig. 3A).
To functionally validate whether APN can mediate its proangiogenic effect independent of
the tumor cells, basic FGF–impregnated Matrigel Matrix preparation was s.c. injected into
either WT or APN KO mice to assess recruitment of vascular endothelial cells. A histologic
examination showed that Matrigel explants from APN KO mice had a significantly lower
cellular content (2.2-fold) with fewer infiltrating cells compared with those from WT control
mice (Fig. 3B). As a negative control, Matrigel devoid of basic FGF was injected, resulting
in very few infiltrating cells in both groups (data not shown). The presence of vascular
channels was examined by immunostaining with anti-CD31 antibody. Figure 3C reveals
elevated blood vessel content in WT compared with the APN KO derived Matrigel.
Combined, these observations lend support for a systemic angiogenic and promigratory
environment in the presence of APN by promoting recruitment of endothelial cells and
possibly additional stromal subpopulations, in addition to shaping the angiogenic profile by
controlling the expression of key factors that are of great potential as targets for
antiangiogenic therapy.
Tumor vasculature in PyMT/APN KO mice is impaired
Given the proangiogenic role of APN in the in vivo model, we reasoned that the lack of APN
may prominently lead to deficiencies under conditions when vascularization is rate-limiting.
We sought to examine the contribution of APN on tumor-associated angiogenesis at times
when lesions have progressed from a pre-malignant to a malignant stage. Total VEGF-A
mRNA levels measured in the mammary gland showed a 2.3-fold increase in PyMT
compared with PyMT/APN KO mice (Fig. 4A). Similarly, mRNA levels of additional
angiogenic markers such as CD31 (1.8-fold), von Willebrand factor (2.3-fold), and VEGFR1
(2.1-fold) were detected at increased levels in PyMT compared with PyMT/APN KO mice
(Fig. 4A). Consistent with these results, immunostaining with anti-CD31 antibody revealed
a 2-fold increase in microvessel density in the mammary glands of PyMT mice relative to
PyMT/APN KO mice (Fig. 4B).
The density of functional vascularization was further assessed by in vivo labeling of the
blood vessels using an i.v. injection of Texas red–conjugated dextran (6). We show that in
the absence of APN, tumors are likely to have diminished functional vascular density (Fig.
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4C and D). This strongly suggests that APN promotes tumor growth, at least in part, by
promoting an angiogenic response during lesion expansion.
Changes in APN levels during tumor expansion
We examined the fluctuations in circulating plasma APN levels over the course of tumor
progression in the PyMT model. By 12 weeks of age, a time point when tumors
characteristically advance to late carcinoma, circulating APN levels were reduced by 44% in
tumor-bearing PyMT mice compared with their WT littermates [Supplementary Fig.
S2A(a)]. Other circulating adipokines such as leptin were down-regulated in both models
independently of the presence of tumors [Supplementary Fig. S2A(b)]. These results show
that APN levels at late tumor stages may not be indicative of the pivotal role of APN at the
early stage of tumorigenesis when its circulating levels are more prevalent, and highlight the
complex dynamic relationship of the tumor with its microenvironment.
In spite of the dramatic reduction in APN levels, fasting glucose and insulin levels were
unaltered as was the glucose excursion during an oral glucose tolerance test done at both
early and late stages of tumor progression (Supplementary Fig. S3). The decline in APN
occurs despite the reduction in fat mass as assessed by whole-body Echo magnetic
resonance imaging analysis (Supplementary Fig. S2B). Loss in fat mass is generally
associated with an increase in plasma APN levels and a positive effect on insulin sensitivity.
In our tumor model, the loss of fat mass does not trigger an increase in APN. This may be
caused by increased local inflammation in the mammary fat pads or may simply be a
reflection of adipocyte loss in the context of increased tumor burden in the mammary fat
pad.
Bypass of the antiangiogenic stress in late-stage mammary tumors of APN KO mice
We next probed for the effects of APN at later stages of tumor progression by measuring
tumor volume. Surprisingly, tumor growth in PyMT/APN KO mice not only caught up but
even far exceeded tumor growth in age-matched PyMT mice at advanced stages of
tumorigenesis, reaching a significant 2.2-fold difference in tumor volume by 14 weeks of
age (Fig. 5A). Differences were also shown histologically: Large solid tumors with some
necrosis in central local regions were present in the PyMT/APN KO tumors, whereas the
PyMT-derived tumors revealed significantly smaller solid tumor regions and no necrotic
regions (data not shown).
PET was applied at this late stage. In contrast to the modest levels of [18F]FDG
accumulation in 9-week-old PyMT/APN KO animals [Fig. 2A(a–b)], 12-week-old PyMT/
APN KO mice showed a massive increase in uptake of [18F]FDG into the mammary glands
(Fig. 5B). This is in agreement with our advanced malignancy phenotype and correlates with
the epidemiologic association of an inverse association between APN and breast cancer risk
(14, 15). Our data suggest that these late-stage tumors arising from a long-term nutrient-
deprived environment in the absence of APN adapt to the anaerobic conditions and emerge
as very aggressive and metabolically highly active cells at later stages in spite of the
presence of an initially deficient vasculature. This coincides with a provocative concept that
has emerged involving the hypothesis that tumors can acclimatize to the presence of
antiangiogenic stress by adaptive mechanisms that may reinitiate and induce tumor growth
(26).
Induced mobilization of CEPs in acclimatized PyMT/APN KO mice
Antiangiogenic treatment can cause recruitment of various bone marrow–derived cells that
have the capacity to fuel tumor growth (26, 28, 38). These bone marrow–derived cells
consist of vascular progenitors and vascular modulatory cells (26). We hypothesized that
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following a period of angiogenic and nutrient deprivation in mice lacking APN, the
mobilization of bone marrow–derived cell subpopulations would be unique to the PyMT/
APN KO mice at late-stage tumorigenesis and may contribute to the rapid surge in growth of
tumors, similar to the situation in tumors that are exposed to pharmacologic antiangiogenic
treatments.
We thus studied mice of both early-stage and late-stage tumors (9 and 12 weeks,
respectively) and assessed circulating bone marrow–derived cell subpopulations in both
PyMT and PyMT/APN KO mice using fluorescence-activated cell sorting. Differences were
observed for CEPs defined as CD45−/CD31+/VEGFR2+/VEGFR1− (27). Differences were
observed only for late-stage tumor–bearing mice, with PyMT/ APN KO showing a 6-fold
increase in circulating levels of CEP subpopulations compared with the age-matched PyMT
animals (Fig. 6A).
Several secreted factors such as stromal-derived factor (SDF-1) and VEGF-A have been
implicated in the recruitment of CEPs into the tumor mass through an endocrine pathway (4,
27). There is also evidence that adipose tissue capillary endothelial cells may secrete SDF-1
(39). We thus measured serum levels of SDF-1 in PyMT and PyMT/APN KO mice. In the
advanced tumor stage, SDF-1 circulating levels were increased by 24% in the PyMT/APN
KO compared with PyMT mice. However, this was not statistically significant (data not
shown). Thus, SDF-1 may provide, at best, only a partial mechanism for CEP recruitment in
our model. We further measured total VEGF-A mRNA levels in tumors, showing a 2.4-fold
up-regulation in PyMT/APN KO compared with PyMT-derived tumors (Fig. 6B). This
correlates with work by others showing increased VEGF-A expression in mice treated with
antiangiogenic inhibitors and was even proposed as a predictive biomarker of tumor
response (26).
We further examined the angiogenic milieu of these late-stage tumors. In contrast to the
elevated VEGF-A mRNA levels measured at this stage (Fig. 6B), other angiogenic markers
that had shown to be decreased in the PyMT/APN KO at the early stage, such as CD31 (1.3-
fold), VEGFR1, and VEGFR2 (Fig. 4), were still either down-regulated or unaltered,
respectively, in the PyMT/APN KO compared with PyMT tumors. This strongly suggests an
alternative pathway of inducing tumor growth when the tumors are deprived of APN for an
extended period of time.
We further examined the tumor vessels to evaluate whether the presence of high levels of
VEGF-A in the tumor is indicative of tumor revascularization, implicating a mechanism to
effectively cope with the absence of APN. No difference was observed in total blood vessel
density. However, qualitatively, the majority of vessels in the PyMT tumors exhibited
dilated and distorted tumor vessels, indicative of vessel remodeling. In contrast, tumor
vessels derived from mice lacking APN showed vessels that were slim, elongated, and with
few tortuous structures, all reflective of normal vasculature [ref. 40; Fig. 6C(a–b)]. These
elongated blood vessels were seen in many cases as major vessels rather than the small,
scattered blood vessels observed in the PyMT tumors [Fig. 6C(c–d)]. This is consistent with
our initial observation that APN is an angio-mimetic adipokine, and it is evident that these
late-stage tumors still lag behind in their angiogenic response.
Transcriptional signature of late-stage APN KO mammary tumors
Given the clinical importance of identifying key factors that are turned on at these advanced
stages of the disease, we decided to use DNA microarrays to more globally asses the
differences in gene expression of late-stage PyMT/APN KO and PyMT tumor samples.
Cluster analysis depicted in Table 1 shows that the most robust differences were observed in
the cancer cluster. A general down-regulation of tumor suppressors such as caveolin 1 (1.4-
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fold) and Rb (1.3-fold) and up-regulation of antiapoptotic genes such as BFAR (4.5-fold)
and DDIT4 (1.6-fold) was observed, in line with our observation of a tumor growth surge in
the absence of APN at this stage of the disease. Importantly, central regulators of
angiogenesis such as matrix metalloproteinase 2 (1.6-fold) and FGF1 (2.9-fold) remained
clearly diminished despite the up-regulation of hypoxia-inducible factor 1α (1.5-fold) and
CXCR4 (1.3-fold). A further reflection of the continued hypoxic environment in these
tumors is the up-regulation of glycolytic genes such as phosphoglycerate kinase 1 and
triosephosphate isomerase 1. These late-stage tumors arising under chronic hypoxic
conditions in the PyMT/APN KO mice have a distinct transcriptional fingerprint that is fully
consistent with a gene expression signature associated with a dramatically more aggressive
tumor phenotype.
Discussion
APN has been implicated in attenuating mammary tumor progression in studies using in
vitro or xenografts models, partially attributable to a postulated role as a negative regulator
of angiogenesis (16–18). However, because there are important differences between the
mechanism of tumor growth and angio-genesis in transplanted and autochthonous tumors
(19, 20, 28), we have analyzed, for the first time, the role of APN in mammary tumor
progression in vivo using the spontaneously occurring mammary tumor model of MMTV-
PyMT. We did this through the use of APN KO mice and by taking advantage of
neutralizing monoclonal antibodies that effectively clear APN from circulation. Contrary to
the published data (16–18), we show that APN can accelerate mammary tumor growth in
vivo at early stages when tumor lesions start to critically depend on angiogenesis for
continued oxygen and nutrient supply. Such a role was also implied in an elegant recent
article that was published in the course of the preparation of this article (41). These authors
suggested the existence of a molecular cross talk between the putative APN receptor T-
cadherin and mammary tumor growth.
Previous in vivo work found that APN promotes angiogenesis in response to tissue ischemia
through the activation of an AMP protein kinase AMPK–dependent signaling pathway (25),
and that APN promotes endothelial cell survival, migration, and differentiation into
capillary-like structures (37, 42). We therefore sought to determine the contribution of APN
to tumor-associated angiogenesis. Our experiments suggest that APN supports the release of
angiogenic factors such as VEGF-A and VEGF-B and can promote blood vessel formation
as judged by an increase in endothelial cell markers such as CD31 and von Willebrand
factor in the PyMT mammary tumors relative to PyMT/ APN KO–derived tumors. Our
experiments using Matrigel implants suggest potent effects of APN that can lead to
extensive reprogramming and induction of blood vessel formation. Importantly, these
experiments, together with the data obtained from our microarray analysis on WT animals
injected with APN, suggest a direct role for APN in the angiogenic response by paracrine
and/or endocrine effects on cell types such as endothelial cells and inflammatory cells,
rather than mediating its effects exclusively through action on the cancer cells.
It is generally accepted that obesity is a risk factor for breast cancer in postmenopausal, but
not premenopausal women (13). Because APN levels are inversely correlated with obesity
(11), it has been suggested that the decreased levels of APN may explain the increased risk
of breast cancer with obesity (14, 15). In fact, numerous retrospective case-controls studies
and a recent prospective study have shown that APN is inversely associated with breast
cancer risk, an association that might be stronger for postmenopausal women (14, 15).
Several observations in the PyMT model are consistent with this inverse association: (a) a
robust decline in circulating APN levels that is observed as the tumor progresses and (b) an
acceleration of mammary tumorigenesis in PyMT/APN KO compared with PyMT in
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advanced malignant stages of the disease. However, similar to the differential effect of
menopausal status in women, a thorough analysis of the PyMT tumor model indicates a
complex role for APN, suggesting a possibly biphasic effect of APN on tumor progression
or, alternatively, the development of an adaptive mechanism at late stages to bypass the
dependence of APN-driven angiogenesis. The switch from a lagging to a more aggressive
tumor growth rate may be a reflection of a Darwinian dynamic similar to what is observed
under conditions of exposure to angiogenesis inhibitors, during which tumors acquire the
ability to survive and proliferate within the suboptimal tumor microenvironment by
activating alternative ways to sustain tumor growth and angiogenesis (26, 36, 43). Similarly,
our data imply that following a prolonged antiangiogenic stress due to the absence of APN,
an adaptive resistant mechanism takes place. A detailed gene expression analysis of the
tumors arising in the PyMT/APN KO mice at late stages reveals easily interpretable changes
in critical genes involved in cancer growth, survival, and enhanced glycolysis. In line with
data that VEGF-A and SDF-1 can induce recruitment of endothelial progenitor cells (4, 44,
45), we show an increase in local VEGF-A in late-stage APN KO tumor–bearing mice that
potentially play a role in the observed robust mobilization of CEPs. This subpopulation of
CEPs has the capacity to enhance tumor growth and has been postulated to be crucial in
situations such as relapse after tumor shrinkage brought about by surgery or antiangiogenic
therapies (27, 28, 38, 46). These results raise the possibility that the recruitment of this
subpopulation contributes functionally to tumor growth in the PyMT/APN KO animals at
late stage, rescuing the cells from their original nutrient-deprived status.
APN critically modulates insulin resistance, atherogenesis, and cardiac remodeling (11). Our
data presented here indicate that it also functions as an angiogenic mediator in mammary
tumors. Our work suggests that vessel development is impaired in mammary tumors lacking
systemic APN, leading to a nutrient-deprived tumor at the early malignant stages. Yet,
alternative pathways are activated at later stages of tumorigenesis to bypass the dependence
on APN and allow for further fueling of tumor growth. Compounds that modulate its
circulating levels such as the PPARγ agonists thiazolindinediones (34, 35) may have a
profound effect on mammary tumorigenesis through the angiogenesis axis (34).
Interestingly, PPARγ agonists have been shown to induce VEGF-A in adipocytes (47) and,
importantly, may be involved in adipose tissue–associated angiogenesis (48). PPARγ is most
abundantly expressed in adipocytes, yet it is also expressed in endothelial and tumor cells,
macrophages, and a number of epithelial tissues including epithelia in the mammary gland
(34). Thus, this class of drugs clearly induces pleiotropic affects in multiple tissues. Taken
together, the effects of PPARγ agonists on the enhancement of mammary tumorigenesis, as
judged by the analysis of these models, may be mediated in part by the cross talk between
APN and the vasculature axis, stimulating tumor growth. In contrast, PPARγ may act as an
antimitogenic factor in tumor cells and as an anti-inflammatory factor in macrophages (34).
The net result of PPARγ stimulation on the transformed ductal epithelium of the mammary
gland raises the distinct possibility that these agonists may enhance neovascularization of
emerging tumors and should be used with caution in a diabetic population with newly
diagnosed malignancies of the mammary gland. On the other hand, tumors arising in an
environment with low APN (such as in an obese and/or diabetic population) may assume a
more aggressive phenotype as suggested by the increased tumor growth at later stages in our
APN KO mice.
Given that elevated levels of CEPs were observed in APN KO mice independent of the
presence or absence of a tumor (data not shown), the proangiogenic role of APN may not
only be relevant under tumor-associated conditions but may also contribute to its potent
antidiabetic effects in our previously described mouse models with moderately elevated
levels of APN achieved through transgenic overexpression. APN enables adipose tissue pads
to massively expand during times of excess caloric intake, allowing a redistribution of
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excess ectopic lipid deposits. Despite the massive hyperplasia of the fat pads in these mice
overexpressing APN, the fat pads remain minimally inflamed and fully insulin sensitive and
do not display the classic hallmarks of expansion under suboptimal conditions, such as
hypoxia and macrophage infiltration (29).
Collectively, our detailed analysis suggests several possible strategies to delay an acquired
adaptation to antiangiogenic stress under conditions when APN abundance is low, such as in
the context of obesity. This includes treatment regimens targeting CEPs, an approach that
has previously been shown to enhance treatment efficacy of cytotoxic chemotherapy (49).
These patients may potentially also show higher sensitivity to chemotherapy given their
normalized vasculature (46, 50). A molecular understanding of the APN-mediated
proangiogenic activity combined with the identification of key stimulating factors that are
turned on at advanced stages of the disease has the potential to reveal novel therapeutic
approaches for breast cancer in blocking both the angiogenic switch and the specific
adaptive pathways that are triggered as a result of chronic angiogenic stress and nutrient
deprivation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
The contributions of stromal adipocytes toward mammary tumor growth have been
appreciated for decades. The effects of adiponectin (APN) on tumor cells are not well
understood, but a number of cancer epidemiologic studies have focused on APN as a
predictive marker. APN levels are becoming a popular and widely measured clinical
parameter, including in the context of breast cancer studies. Here, we present the first in
vivo data on the role of APN on mammary tumor growth and highlight its function as a
potent proangiogenic factor. APN is a key mediator of the antidiabetic actions of the
widely used peroxisome proliferator–activated receptor γ agonists (thiazolindinediones).
These compounds lead to an increased tumor mass in the present studies. Our data
suggest a possible mechanism for the increased risk and poorer prognosis seen in breast
cancer patients with low serum APN levels (such as obese women) due to acquired
adaptation of tumors to antiangiogenic stress.
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Fig. 1.
PyMT/APN KO mice display delayed mammary tumor progression. A, top, representative
whole-mount preparations of inguinal mammary gland derived from age-matched 7-wk-old
mice. Bar, 1 mm. Bottom, total lesion area of PyMT and PyMT/APN KO at 5 wk (n = 4–6
per group) and 7 wk (n = 11–12 per group; bars, SE; *, P < 0.05). B, summary of tumor
staging distribution derived from H&E of 7-wk-old inguinal mammary glands sections (n =
13 per group). C, a representative experiment is shown at the top. Western blot
quantification of circulating APN levels in mice treated with monoclonal antibodies
neutralizing APN (bars, SE; *, P < 0.001, two-way ANOVA). Bottom, APN neutralizing
antibody–treated mice (n = 6) show a trend of a 2-fold decrease in lesion area compared
with IgG-treated mice (n = 3) as measured in whole mounts of inguinal mammary glands
(bars, SE; P = 0.2). D, mice were treated with either vehicle or the PPARγ agonist COOH
from 4 to 9 wk of age. Total lesion area from whole mounts was measured. PyMT mice
treated with the PPARγ agonist have a 35% increase in lesion area compared with vehicle-
treated PyMT, whereas PyMT/APN KO mice treated with the PPARγ agonist show a more
modest increase in lesion area compared with the untreated PyMT/APN KO group (n = 9–10
per group; bars, SE; *, P < 0.05).
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Fig. 2.
Decreased accumulation of [18F]FDG as assessed by microPET and increased tumor-
associated death in PyMT/APN KO tumor–bearing mice. A, coronal images showing the
mammary tumor spread (arrows) in addition to bladder (*) and heart (**) that have a high
glucose uptake. By 9 wk of age, PyMT mice (n = 4–5) displayed an 11-fold increase in
[18F]FDG uptake in the mammary glands compared with age-matched PyMT/APN KO mice
(a and b; n = 4; bars, SE; *, P < 0.05). B, H&E staining showing necrotic regions (N) in
mammary tumors (T) lacking APN; no necrotic regions were observed in age-matched
mammary tumors of PyMT mice (n = 21 per group). C, quantitative analysis of TUNEL
staining in 9-wk-old PyMT mice and PyMT/APN KO mice (n = 6 per group; bars, SE; *, P
< 0.05). Bar, 100 μm (B), 20 μm (C).
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Fig. 3.
APN as a positive regulator of angiogenesis independent of tumor cells. A, gene expression
profiling of the epididymal fat tissue was determined by microarray analysis. Results are
expressed as the fold change in gene expression in WT mice treated with APN injections
compared with WT mice treated with vehicle (n = 3 per treated group, n = 10 per control
group). *, P < 0.005; **, P < 0.01. B and C, mice were s.c. injected with Matrigel + basic
FGF. B, a representative H&E staining of the Matrigel matrix (a and b). Image J
quantification shows a >2-fold difference between the WT and APN KO Matrigel cellular
content (c; bars, SE; *, P < 0.05; n = 6 per group). C, a representative immunohistochemical
staining for CD31 endothelium (n = 4 per group). Dashed lines, Matrigel region. Red arrow,
enlarged section. Bar, 100 μm [C (a and c)]; 20 μm [B (a and b) and C (b and d)].
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Fig. 4.
PyMT/APN KO show a decrease in the angiogenic profile. A, mammary glands were
excised and mRNA levels were quantified by real-time PCR; β-actin was used as an internal
control (*, P < 0.05; n = 5–8 per group). B, immunohistochemistry analysis of CD31
endothelium (bars, SE; *, P < 0.05; n = 5 per group). C, vessel density evaluation in tumor
sections from Texas red-dextran–injected mice counterstained with 4′,6-diamidino-2-
phenylindole. Bar, 50 μm. D, inguinal mammary gland was imaged for vessel density
distribution and compared between PyMT (n = 7) and PyMT/APN KO mice (n = 5; bars,
SE; P = 0.15).
Landskroner-Eiger et al. Page 20
Clin Cancer Res. Author manuscript; available in PMC 2011 December 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 5.
Late-stage tumorigenesis: PyMT/APN KO mice display an adaptive phenotype. A, average
values are presented for the longitudinal measurements of the first palpable tumors. PyMT, n
= 28; PyMT/APN KO, n = 21 (bars, SE; *, P < 0.05, two-way ANOVA). B, coronal images
showing the mammary tumor spread (arrows) in addition to bladder (*) and heart (**) that
have a high glucose uptake as measured by microPET. Twelve-week-old PyMT/APN KO
mice (n = 4) showed comparable glucose uptake to PyMT mice (n = 7).
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Fig. 6.
PyMT/APN KO mice initiate mobilization of circulating endothelial progenitor cells during
late-stage tumorigenesis. A, fluorescence-activated cell sorting analysis of CEPs levels in
circulation, showing a 6-fold increase in PyMT/APN KO compared with PyMT mice (bars,
SE; *, P < 0.05; n = 5–7 mice per group). B, inguinal mammary tumors were excised and
mRNA levels were quantified by real-time PCR (**, P = 0.07; *, P < 0.05; n = 5–7 per
group). C, tumors were imaged for blood vessel morphology using CD31 antibody. PyMT
tumors exhibited dilated and torturous tumor vessels (a, c). In contrast, PyMT/APN KO
blood vessels showed slim and elongated characteristics (b, d; n = 4 per group). Bar, 50 μm.
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Table 1
Differential gene expression in PyMT/APN KO versus PyMT in late-stage tumors
Genes up-regulated in PyMT/APN KO tumors
Cluster Gene name Accession no. Fold change
Cancer ST6GAL1 NM_1459332.2 1.6
HIF1a NM_010431.1 1.5
MAPKS1P1 NM_011162.2 1.5
PGK1 NM_008828.2 1.5
PTGS1 NM_008969.1 1.3
CXCR4 NM_009911.2 1.3
HDAC5 NM_010412.2 1.3
CDKN1B NM_009875.2 1.2
Cell death BFAR NM_025976 4.5
DD1T4 NM_029083.1 1.6
LGALS7 NM_008496.4 1.6
MAPK81P1 NM_011162.2 1.5
MMP13 NM_008607.1 1.3
Glycolysis PGK1 NM_008828.2 1.5
TP11 NM_009415.1 1.4
Genes down-regulated in PyMT/APN KO tumors
Cancer FGF1 NM_010197.2 2.9
MMP2 NM_008610.1 1.6
AXL A1323647 1.5
CAV1 NM_007616.2 1.4
RB1 NM_009029.1 1.3
CCR5 NM_9919.2 1.3
MMP1 NM_032006.2 1.2
TLR4 NM_021297.1 1.2
Cell death TNFRSF10 NM_020275.3 1.6
IL15RA NM_133836.1 1.4
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